Morris Gabriel S 4

What Happened
Gabriel S. Morris, who serves as Chief Financial Officer, President and a Director of Immix Biopharma (IMMX), was granted 500,000 derivative shares (a stock option award) on 2026-05-22. The grant shows a $0.00 per‑share price in the filing, meaning no cash was paid by Morris for the award at grant. This is a compensation/award transaction rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-22; Filing posted: 2026-05-29 (check timeliness vs. the typical 2-business‑day Form 4 deadline).
• Security/amount: 500,000 derivative shares (stock option award) at $0.00 per share.
• Vesting: The award vests in 48 equal monthly installments beginning on the grant date, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• Nature: Award/compensation (code A) — not an open‑market trade or a cash exercise; no immediate proceeds or sales were reported.

Context: This grant is a standard equity compensation award for an executive and does not represent an immediate cash investment or sale. Because the options vest over four years monthly, these shares will only become exercisable/owned over time if Morris remains employed and any applicable exercise conditions are met.